Photo via flickr by teo_ladodicivideo

The Peripheral and Central Nervous System Drugs advisory committee of the FDA has voted to recommend DaTSCAN, (Ioflupane I 123 Injection). If approved, GE Healthcare’s DaTSCAN™ will be the first radiopharmaceutical agent available to detect DaT (dopamine transporter) distribution within the brain. The proposed indication for DaTSCAN™ is for the visualization by single photon emission computed tomography (SPECT) imaging in patients presenting symptoms or signs of dopaminergic neurodegeneration.

via Reuters

This entry was posted on Tuesday, September 8th, 2009 at 9:04 am by obsrvtry and is filed under F is for Frequency. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.